Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling.

ABSTRACT:

Background

Glioblastoma (GBM) is a lethal type of primary brain tumor with a median survival less than 15 months. Despite the recent improvements of comprehensive strategies, the outcomes for GBM patients remain dismal. Accumulating evidence indicates that rapid acquired chemoresistance is the major cause of GBM recurrence thus leads to worse clinical outcomes. Therefore, developing novel biomarkers and therapeutic targets for chemoresistant GBM is crucial for long-term cures.

Methods

Transcriptomic profiles of glioblastoma were downloaded from gene expression omnibus (GEO) and TCGA database. Differentially expressed genes were analyzed and candidate gene PLK2 was selected for subsequent validation. Clinical samples and corresponding data were collected from our center and m

SUBMITTER: Alafate W 

PROVIDER: S-EPMC7657349 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature